Reauthorizes the Accelerating Access to Critical Therapies for ALS Act through fiscal year 2031.

The Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 extends the Accelerating Access to Critical Therapies for ALS Act through fiscal year 2031. It amends the definition of "phase 3" clinical trials to include phase 2/3 combined trials and planned phase 3 trials not yet enrolling participants. The Secretary of Health and Human Services must assess clinical trial status and request interim trial data for investigational drugs.

Reauthorizes the Accelerating Access to Critical Therapies for ALS Act through fiscal year 2031.

The Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 extends the Accelerating Access to Critical Therapies for ALS Act through fiscal year 2031. It amends the definition of "phase 3" clinical trials to include phase 2/3 combined trials and planned phase 3 trials not yet enrolling participants. The Secretary of Health and Human Services must assess clinical trial status and request interim trial data for investigational drugs.